Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Veracyte (VCYT) over the last 12 years, with Q3 2025 value amounting to $417000.0.

  • Veracyte's Current Deferred Revenue fell 7948.84% to $417000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $417000.0, marking a year-over-year decrease of 7948.84%. This contributed to the annual value of $1.7 million for FY2024, which is 1668.33% down from last year.
  • According to the latest figures from Q3 2025, Veracyte's Current Deferred Revenue is $417000.0, which was down 7948.84% from $1.4 million recorded in Q2 2025.
  • Veracyte's 5-year Current Deferred Revenue high stood at $4.9 million for Q1 2022, and its period low was $417000.0 during Q3 2025.
  • Its 5-year average for Current Deferred Revenue is $2.4 million, with a median of $2.2 million in 2024.
  • In the last 5 years, Veracyte's Current Deferred Revenue skyrocketed by 115229.11% in 2021 and then plummeted by 7948.84% in 2025.
  • Veracyte's Current Deferred Revenue (Quarter) stood at $4.6 million in 2021, then plummeted by 43.76% to $2.6 million in 2022, then decreased by 23.15% to $2.0 million in 2023, then decreased by 16.68% to $1.7 million in 2024, then tumbled by 75.07% to $417000.0 in 2025.
  • Its Current Deferred Revenue was $417000.0 in Q3 2025, compared to $1.4 million in Q2 2025 and $1.7 million in Q1 2025.